Category:Schedule II controlled substances: Difference between revisions
Category page
More actions
Create canonical category-page article (history-first) |
Rewrite per canonical category-page spec (history-first article) |
||
| Line 9: | Line 9: | ||
Several Schedule II medicines exist principally as scheduling artefacts of compounding regulations. [[wikipedia:Pentobarbital|Pentobarbital]] and [[wikipedia:Secobarbital|secobarbital]] (Schedule II [[:Category:Barbiturates|barbiturates]]) and [[wikipedia:Amobarbital|amobarbital]] (Schedule II as the parent; in combination with other ingredients drops to Schedule III) remain in occasional use for refractory status epilepticus, for medically assisted dying in the jurisdictions where the practice is legal, and (in Mexico and the United Kingdom) for veterinary euthanasia. Several precursor chemicals (anhydrous hydrogen iodide and red phosphorus, key precursors of methamphetamine synthesis) are also Schedule II, although these are regulated under separate sections of the CSA that affect manufacturers and chemists rather than prescribers. | Several Schedule II medicines exist principally as scheduling artefacts of compounding regulations. [[wikipedia:Pentobarbital|Pentobarbital]] and [[wikipedia:Secobarbital|secobarbital]] (Schedule II [[:Category:Barbiturates|barbiturates]]) and [[wikipedia:Amobarbital|amobarbital]] (Schedule II as the parent; in combination with other ingredients drops to Schedule III) remain in occasional use for refractory status epilepticus, for medically assisted dying in the jurisdictions where the practice is legal, and (in Mexico and the United Kingdom) for veterinary euthanasia. Several precursor chemicals (anhydrous hydrogen iodide and red phosphorus, key precursors of methamphetamine synthesis) are also Schedule II, although these are regulated under separate sections of the CSA that affect manufacturers and chemists rather than prescribers. | ||
The clinical implications of the Schedule II classification go well beyond the additional paperwork. The 1996 introduction and aggressive marketing of [[wikipedia:OxyContin|controlled-release oxycodone (OxyContin)]] was followed by a two-decade rise in opioid prescribing, dependence, and overdose mortality that has been the subject of substantial legal action against the manufacturer ([[wikipedia:Purdue Pharma|Purdue Pharma]]) and its owners. The contemporary regulatory environment of Schedule II prescribing reflects that history: state PDMP consultation is now mandatory in 49 states for opioid prescriptions; CMS audit and the corresponding fear of regulatory consequence have measurably reduced opioid prescribing in primary care; and the "OUD" (opioid use disorder) and "MAT" ( | The clinical implications of the Schedule II classification go well beyond the additional paperwork. The 1996 introduction and aggressive marketing of [[wikipedia:OxyContin|controlled-release oxycodone (OxyContin)]] was followed by a two-decade rise in opioid prescribing, dependence, and overdose mortality that has been the subject of substantial legal action against the manufacturer ([[wikipedia:Purdue Pharma|Purdue Pharma]]) and its owners. The contemporary regulatory environment of Schedule II prescribing reflects that history: state PDMP consultation is now mandatory in 49 states for opioid prescriptions; CMS audit and the corresponding fear of regulatory consequence have measurably reduced opioid prescribing in primary care; and the "OUD" (opioid use disorder) and "MAT" (the older term for medicine-assisted treatment, now usually styled "MOUD" for medicines for opioid use disorder) infrastructure of [[Buprenorphine|buprenorphine]] (Schedule III), [[Methadone|methadone]] (Schedule II via opioid-treatment programmes), and extended-release naltrexone has developed in parallel. The Schedule II classification is, in clinical practice, a marker that prescribing carries regulatory consequence in addition to clinical responsibility. | ||
== Selected medicines indexed == | == Selected medicines indexed == | ||